- Home
- ARMP vs BANX Comparison
ARMP vs BANX Comparison
Compare ARMP & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARMP | BANX |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.7M | 149.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARMP | BANX |
|---|---|---|
| Price | $7.35 | $21.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 99.2K | 23.4K |
| Earning Date | 11-12-2025 | 06-17-2025 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | $5,054,000.00 | ★ $29,467,794.00 |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.88 |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $0.90 | $17.99 |
| 52 Week High | $16.34 | $21.67 |
Technical Indicators
Market Signals| Indicator | ARMP | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 61.16 |
| Support Level | $6.81 | $21.03 |
| Resistance Level | $7.40 | $21.75 |
| Average True Range (ATR) | 0.67 | 0.33 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 89.99 | 100.00 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.